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Abstract
Streptococcus pneumoniae causes invasive infections, primarily at the extremes of life. A seven-valent conjugate vaccine
(PCV7) is used to protect against invasive pneumococcal disease in children. Within three years of PCV7 introduction, we
observed a fourfold increase in serotype 6C carriage, predominantly due to a single clone. We determined the whole-
genome sequences of nineteen S. pneumoniae serotype 6C isolates, from both carriage (n = 15) and disease (n = 4) states, to
investigate the emergence of serotype 6C in our population, focusing on a single multi-locus sequence type (MLST) clonal
complex 395 (CC395). A phylogenetic network was constructed to identify different lineages, followed by analysis of
variability in gene sets and sequences. Serotype 6C isolates from this single geographical site fell into four broad
phylogenetically distinct lineages. Variation was seen in the 6C capsular locus and in sequences of genes encoding surface
proteins. The largest clonal complex was characterised by the presence of lantibiotic synthesis locus. In our population, the
6C capsular locus has been introduced into multiple lineages by independent capsular switching events. However, rapid
clonal expansion has occurred within a single MLST clonal complex. Worryingly, plasticity exists within current and potential
vaccine-associated loci, a consideration for future vaccine use, target selection and design.
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Introduction
Streptococcus pneumoniae (the pneumococcus) causes life-threaten-
ing invasive disease (pneumonia, septicaemia, and meningitis),
primarily in children and the elderly, as well as other less severe
infections (sinusitis, and acute otitis media). The global burden of
pneumococcal invasive disease was estimated at almost 15 million
cases in 2000.[1] Asymptomatic carriage is known to precede
invasive disease and young children are the major reservoir of
pneumococci in human populations, around one-third of children
under five and over half of those under two carried S. pneumoniae
asymptomatically in the nasopharynx.[2–4]
The pneumococcus is naturally transformable and shows
considerable genotypic and phenotypic diversity, particularly in
capsular serotype, of which over 90 are known. Capsular serotype
is associated with the ability to cause invasive disease—around a
quarter of the known serotypes account for the majority of invasive
infections; some serotypes are at least ten-fold more likely to cause
invasive disease than others.[5]
The seven-valent pneumococcal conjugate vaccine (PCV7) was
licensed in the USA and Europe just over ten years ago. The
vaccine consists of the polysaccharide capsule of seven serotypes
associated with paediatric invasive disease in North America (4,
6B, 9V, 14, 18C, 19F and 23F), conjugated to diphtheria toxoid. It
was added to the childhood immunisation schedule in the USA in
2001 but not added to the UK’s schedule until 2006. The use of
PCV7 resulted in a reduction of invasive pneumococcal disease
both in the North America and Europe.[6–9] However, since the
introduction of PCV7, ‘‘serotype replacement’’ has been observed,
with an increase in the proportion of invasive and non-invasive
disease caused by serotypes not represented in the vaccine.[10,11]
In the UK, the increased incidence of invasive pneumococcal
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disease was caused by serotypes not included in the seven-valent
vaccine to some extent offset the impact of PCV7.[9] For this
reason, PCV7 has recently been replaced in UK and US
vaccination schedules with PCV13, which provides coverage for
six additional serotypes.
Serotype 6C was first described in 2007 as a subtype of 6A that
differed in reactivity with monoclonal antibodies from the majority
of 6A strains.[12] PCV7 contains polysaccharide from the 6B
serotype, which provides protection against serotypes 6A and
6B.[13] However, such protection does not extend to serotype
6C.[14] Serotype 6C appears to be rare in pre-vaccination
populations.[15–21] However, a worrying increase in the
incidence of serotype 6C disease and carriage has been observed
in diverse populations around the world since the introduction of
PCV7.[22–32] Locally, since the introduction of PCV7, we have
seen a fourfold increase in the proportion of nasopharyngeal
serotype 6C isolates among pneumococci isolated from our study
population in Southampton, England—from 3.8% of all isolates in
the winter of 2006/7 to 13.5% and 13.7% in the winters of 2007/
8 and 2008/9 respectively.[2,33] Worryingly, we have also seen
fatal cases of serotype 6C invasive disease.
Sustained surveillance and identification of factors influencing
serotype distribution are essential for the continued control of
pneumococcal disease and for rational vaccine design. Multi-locus
sequence typing (MLST) has been used extensively to investigate
the population structure of S. pneumoniae.[34] Although there is a
correlation between MLST type and serotype, isolates from within
a serotype can belong to a number of individual clonal complexes
or sequence types and isolates of the same sequence type can
express different capsular polysaccharides. Vaccine usage can
result in capsular switching, where an existing sequence type from
one capsular serotype remains prevalent by acquiring a different
capsular locus.[35] Phylogenetic analyses of biosynthetic loci
suggest that all 6C isolates belong to a single clade.[36] However,
MLST studies on serotype 6C have shown it to encompass over
two-dozen sequence types, several shared with the 6A sero-
type.[26,27,30,36]
It is clear that pneumococcal strains from the same sequence
type and/or serotype can differ significantly in gene content and
virulence-associated phenotypes.[37] However, as MLST sam-
ples neutral sequence variation within a handful of housekeep-
ing genes, it cannot always provide information about differ-
ences in gene repertoire or sequence variation within loci
associated with virulence. Furthermore, MLST cannot discrim-
inate between very closely related isolates. We therefore turned
to a more informative approach: high-throughput whole-
genome sequencing. Several recent studies have shown that
this approach is capable of the ultimate resolution of a single
nucleotide base-pair change (SNP) between isolates while also
providing valuable information on differences in virulence loci
and gene content.[38–41]
Recombination is the major driving force for short-term
genome evolution in the pneumococcus—an early MLST study
suggested that a single nucleotide site is approximately 50 times
more likely to change through recombination than mutation,
while a more recent whole-genome-sequencing study estimated
that 88% of SNPs in the Pneumococcal Molecular Epidemiol-
ogy Network clone1 (PMEN1) lineage were the result of
recombination events.[41,42] This high level of recombination
distorts, but does not eliminate, phylogenetic signals of descent
within pneumococcal lineages. However, given that recombi-
nation is so pervasive in pneumococci, evolutionary relation-
ships between isolates are best represented by phylogenetic
networks rather than by trees.[43]
Study goals
We undertook whole-genome sequencing of multiple local
isolates from serotype 6C to investigate genetic diversity within a
single serotype in a constrained geographical location and time
period, focusing on the sequence type driving current 6C
expansion in our study population, ST1692. We used whole-
genome sequencing of serotype 6C pneumococcal isolates from
Southampton to address the following questions:
1. Can genome sequencing provide information comparable or
superior to MLST on the evolution and spread of serotype 6C
lineages within a single geographical location?
2. Are there differences in gene content among the serotype 6C
strains circulating in our community and might these
differences account for variation in the prevalence of different
lineages?
3. Is there heterogeneity in capsule regions or other virulence
factors that might influence virulence and impact on the
development of future vaccines?
Methods
Bacterial isolates
Samples were collected during the winters of 2006-07, 2007-08
and 2008-09. To obtain pneumococcal carriage isolates, nasopha-
ryngeal swabs were collected from children aged four years and
under with written parental/guardian informed consent; ethical
approval for this proceedure was obtained from Southampton and
South West Hampshire Research Ethics Committee ‘B’ [REC 06/
Q1704/105]. Samples were collected regardless of health and
vaccination status, gender or ethnicity and no demographic data
were collected. Children were swabbed only once. All serotype 6C
invasive disease isolates (n = 4) from blood or cerebrospinal fluid
specimens received by the HPA South East regional microbiology
laboratory between 2006 and 2010 were included; these were all
from adult patients. Microbiological procedures were performed
as previously described.[2] Pneumococcal capsular typing was
performed on genomic DNA isolated from sub-cultured isolates by
multiplex PCR.[2] Multi-locus sequence type (MLST) was
determined by Qiagen Genomic Services, using the MLST
website www.mlst.net to assign sequence type (ST).[2,34]
Thirty-two serotype 6C isolates were obtained from the carriage
samples, falling into nine sequence types, of which ST1692
(belonging to clonal complex 395) was the most common (n= 18);
three of the four invasive-disease isolates also belonged to ST
1692/CC395. CC395 was defined as all isolates within ST395 or
within sequence types which shared 6/7 of MLST alleles with
ST395. CC395 therefore encompassed nine isolates from ST1692,
two representatives of ST1714 and a single representative of
ST395. Fifteen of the 32 6C carriage isolates (47%) and four
invasive disease isolates were selected for whole-genome sequenc-
ing (Table 1). These included at least one representative of each of
the nine observed sequence types, with twelve isolates from CC395
(Table 1, Figure 1, 2).
Procedures
DNA was extracted for whole-genome sequencing from an
approximately 1010 bacterial cell pellet of obtained from six hours
liquid culture in 10 ml of liquid culture Brain-Heart-Infusion
(BHI) for whole-genome sequencing. Extraction was performed
using the Qiagen 100/G genomic tips by following the manufac-
turer’s instruction for Gram-positive bacteria. All strains were
shotgun-sequenced by 454 (Roche, Welwyn Garden City) using
Clonal Expansion of Serotype 6C
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Titanium reagents at the University of Birmingham sequencing
service. The reference strain SOT2073 was also sequenced with
454 mate-pair sequencing with an insert size of 8 kb to produce a
single-scaffold reference sequence. All sequences were submitted to
the short-read archive (http://www.ncbi.nlm.nih.gov/sra) and are
available under the accession number SRP013270.
An average of 40 million bp were generated per isolate, yielding
approximately 19-fold coverage per genome. Mean read lengths
were 331 bp. A de novo assembly was performed for each strain,
using Newbler version 2.5 (Roche) under default settings except
that the ’-rip’ was invoked, which ensures that each read is placed
in a single contig only. De novo assembly of each strain produced a
mean of 167 contigs across all assemblies with a mean N50 (a
statistical measure of the average length of a set of sequences) of
39753 base-pairs. Assembly of the strain SOT2073 data, including
paired-end information, generated a single scaffold, 2,129,664bp
in length, generally co-linear with the genome sequence of the
well-characterised strain R6 (data not shown).
Assemblies were submitted to the xBASE annotation service
(http://www.xbase.ac.uk/annotation) to provide an initial set of
gene predictions. Orthologous genes were predicted from these
annotated genomes in conjunction with complete S. pneumoniae
genome sequences retrieved from GenBank using OrthoMCL
(www.orthomcl.org) Whole-genome phylogenies were calculated
from the core genome (defined as the set of single-copy
orthologous genes present in all strains). Individual alignments of
orthologues were produced by MUSCLE and trimmed for quality
in Gblocks.[44,45] The resulting alignments were concatenated
into a single super-alignment and phylogenetic networks created
using SplitsTree drawing on genomes of representative strains in
the public databases. Additionally, whole-genome alignments were
produced in Mauve and analysed with ClonalFrame to remove
signals of recombination to provide phylogenetic signals of vertical
descent. The datasets generated by this study, including assem-
blies, annotations, orthologue predictions and alignments have
been deposited in a Github repository (http://github.com/
nickloman/pneumococcus-6C-study).
For accurate read mapping of the capsule locus reads were
mapped against the SOT2073 reference sequence using the
gsMapper component of Newbler. SNP calls were also produced
in this way. SNPs were filtered using a variant frequency cut-off of
100% and the effect on protein sequence determined using xBASE.
Figure 1. A phylogenetic split-network showing the relationship between Southampton 6C strains and other strains with whole-
genome data from the public database. To generate the split-network, single nucleotide variants in concatenated multiple alignments of S.
pneumoniae core genome coding sequences were input to a Neighbour-Net analysis in SplitsTree. Strains sequenced in this study are coloured in
green. The serotype of each strain is shown in parenthesis.
doi:10.1371/journal.pone.0064731.g001
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Results
Clonal diversity and clonal expansion
We identified SNPs in the genes conserved in all our isolates and
other representative S. pneumoniae strains. From these, we
generated a phylogenetic split-network (Figure 1), which largely
reproduces the major pneumococcal lineages described by Donati
et al.[43] Our serotype 6C isolates fall into four lineages. The
largest 6C lineage consists of the twelve isolates belonging to clonal
complex 395, together with SOT3050 from ST1600 and
SOT0113 from ST65. Two serotype 6C isolates from ST1150—
one associated with carriage (SOT3060), the other with fatal sepsis
(SOT1060N) —form a distinct phylogenetic cluster. Two other
seemingly unrelated serotype 6C carriage isolates, SOT2300
(ST1862) and SOT3088 (ST398) also form a distinct cluster. One
carriage isolate from this serotype, SOT2029 from ST3460, sits
separate from all other serotype 6C strains.
We next focused on diversity within this clonal complex,
creating a phylogenetic network of CC395 strains (Figure 2). Tight
clustering was found between four pairs of strains. The close
relationship between SOT2073 and SOT2074 is unsurprising
because these strains were collected from siblings in the same
family during the same hospital visit. Nonetheless, there are seven
SNPs that separate these genomes, three of them apparently
acquired through recombination. Four of the seven SNPs occur in
coding regions and three representing non-synonymous changes,
emphasising the relatively fast pace of genome evolution in this
species.
There are two pairs of carriage isolates (SOT0081/SOT3022
and SOT0237/SOT3074) where the isolates were obtained two
years apart, yet cluster together tightly, suggesting that conserved
genotypes can persist year on year. More worryingly, two of the
four invasive isolates, SOT0802M and SOT1058S cluster
Table 1. Pneumococcal isolates selected for whole genome
sequencing.
Identifier Year
Specimen
type
Clinical Status and
Outcome ST
SOT0802M 2008 Blood COPD exacerbation:
Recovered
ST1692
SOT0954Q 2009 Blood Pneumonia: Fatal ST1692
SOT1058S 2010 CSF Meningitis: Fatal ST1692
SOT1060N 2010 Blood Sepsis: Fatal ST1150
SOT0081 2006/7 NP swab Carriage ST1692
SOT0113 2006/7 NP swab Carriage ST65
SOT0237 2006/7 NP swab Carriage ST1714
SOT2029 2007/8 NP swab Carriage ST3460
SOT2073 2007/8 NP swab Carriage ST1692
SOT2074 2007/8 NP swab Carriage ST1692
SOT2105 2007/8 NP swab Carriage ST1692
SOT2300 2007/8 NP swab Carriage ST1862
SOT2371 2007/8 NP swab Carriage ST395
SOT3022 2008/9 NP swab Carriage ST1692
SOT3050 2008/9 NP swab Carriage ST1600
SOT3055 2008/9 NP swab Carriage ST1692
SOT3060 2008/9 NP swab Carriage ST1150
SOT3074 2008/9 NP swab Carriage ST1714
SOT3088 2008/9 NP swab Carriage ST398
Abbreviations: CSF: cerebrospinal fluid; NP: nasopharyngeal.
doi:10.1371/journal.pone.0064731.t001
Figure 2. A phylogenetic split-network drawn from single nucleotide variants showing the relationship between CC395 isolates.
Invasive isolates are coloured in red.
doi:10.1371/journal.pone.0064731.g002
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together, yet were also obtained from samples two years apart,
suggesting the persistence of a virulent clone carrying a serotype
not covered by the PCV-7 vaccine.
Sequence variation in loci associated with surface
structures
Mapping alignments revealed that the number of SNPs
separating each isolate from SOT2073 ranged from 8 to 19,829
among our serotype 6C isolates. Up to 128 SNPs were seen in
isolates from ST1692 and up to 172 SNPs within the CC395
clonal complex (Table 2). Surprisingly, the majority of SNPs were
non-synonymous, probably reflecting selective pressure on key
virulence determinants. Known or putative virulence factors are
commonly mutated including the IgA1 protease, choline-binding
proteins, surface proteins PspA and PspC and endo-beta-N-
acetylglucosaminidase. All isolates from CC395, together with
isolate SOT3050 (ST1600), encode a second PspA-domain
protein, not seen in any of the other sequence types. This protein
contains two domains: a glucan domain with homology to PspA
and a peptidase/caspase domain. The pair of invasive isolates,
SOT0802M and SOT1058S, also show variation in the choline-
binding protein PspC, in particular in the length of a proline-
alanine repeat motif, linking the C-terminal choline-binding
domain and the active peptide domain.
The 6C capsular locus is thought to have originated at least
three decades ago in a single recombination event that
replaced the 6A wciN gene (encoding a glysoyltransferase) with
the wciN-beta allele.[36,46] However, we found heterogeneity
in capsular gene sequences—in particular, several stretches
from the capsular locus of isolate SOT0113 showed ,95%
sequence identity to the reference sequence from SOT2073
and other 6C isolates. Also, a previous described insertion in
the wzy gene was found in SOT0113, but not in the other
isolates examined.[47]
Accessory genome of 6C serotype strains
Next, we examined the accessory genome of our serotype 6C
isolates, that is the set of genes and gene clusters not present in all
strains of S. pneumoniae. The largest differences in gene content
between our 6C isolates and the SOT2073 reference genome were
due to prophages, for example a near-identical ,13 kb prophage
in the two ST1714 isolates and the ,32-kb Streptococcus phage
11865 in SOT3055. Prophages are known to carry virulence-
related genes in many other bacterial species and, although a
relatively underexplored topic, this is probably also true in the
pneumococcus.[48,49]
Our survey revealed several putative resistance genes within the
6C serotype. As noted, SOT2029 clusters separately from all other
serotype 6C strains. Interestingly, this isolate, shows resistance to
erythromycin and tetracycline but not penicillin (minimum
inhibitory concentrations of .256, 6 and 0.064 respectively) and
carries the ermB and tetM genes flanked by genes associated with
conjugative transposons. All of the other isolates were sensitive to
penicillin, tetracycline and erythromycin, and none contained
sequences for ermB and tetM genes. All of our isolates from CC395
carry a lantibiotic synthesis locus not seen in any of the other
serotype 6C sequence types we have studied. A very similar locus
has been described in two other genome-sequenced S. pneumoniae
isolates, CGSP14 and INV200.[50] However, these belong to a
different serotype and are not related to CC395 in our
phylogenetic network, suggesting that this cluster has undergone
horizontal gene transfer.
Discussion
This study illustrates the evolution of a single pneumococcal
serotype, 6C, during a period of vaccine pressure. The scattered
phylogenetic distribution of serotype 6C isolates provides
convincing evidence for historical capsular serotype switch-
ing,[32] whereby the 6C capsular locus has been introduced
into multiple pneumococcal lineages by independent recombi-
nation events. However, the phylogenetic network also confirms
that, in our local population, the rise in prevalence of serotype
6C is largely due to clonal expansion within a single clonal
complex.
The presence of a lantibiotic synthesis locus within and unique
to all genome-sequenced members of this clonal complex provides
a possible explanation for the success and clonal expansion of
CC395 in our study group. Lantibiotics are bacteriocins that
contain the modified amino acid lanthionine and which are
produced by, and act on, Gram-positive bacteria.[51] Their
ecological role is thought to impart colonisation resistance,
preventing related strains from gaining a foothold in a specific
environment [51,52]. Our genomic survey suggests that lantibiotic
production may have enhanced the fitness of CC395 in the
presence of other S. pneumoniae lineages in a competitive and
shifting environment, potenitally explaining its increasing pre-
dominance in our sample set.
As expected from previous studies, we found little or no
variation in the complement or sequences of metabolic genes.
Instead, we found a serotype 6C accessory genome largely
composed of prophage genes. However, we did find further
evidence of sequence variation within loci encoding surface
structures, both proteins and capsular polysccahride, presumably
driven by selective forces imposed by the host immune system.
This is worrying for two reasons. Firstly, although the new vaccine
Table 2. Single nucleotide polymorphisms.
Strain ST Total SNP Filtered CDS
Non-
Synonymous
SOT2074 1692 81 8 4 3
SOT2105 1692 217 67 49 30
SOT3022 1692 233 73 51 29
SOT802M 1692 202 100 77 45
SOT1058S 1692 237 109 77 46
SOT0081 1692 189 111 80 48
SOT954Q 1692 251 111 70 45
SOT3055 1692 304 128 102 70
SOT0237 1714 334 156 122 83
SOT3074 1714 353 161 123 82
SOT2371 395 367 172 123 81
SOT0113 65 16772 2466 2042 636
SOT2029 3460 18835 12148 10360 2977
SOT3050 1600 16534 13777 11551 3494
SOT3060 1150 17824 13892 11935 3466
SOT3088 398 17735 14506 12275 3721
SOT1060N 1150 19298 15832 13403 3874
SOT2300 1862 24959 19829 17209 5054
The number of filtered SNPs separating isolates from SOT2073 ranges from 8 to
19,829. Within ST1692 the largest number of SNPs is 304;within CC395, the
largest number is 367.
doi:10.1371/journal.pone.0064731.t002
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PCV13 appears to provide protection against the 6C serotype,[53]
our findings suggest that sufficient plasticity might exist within the
6C capsular locus for new vaccine-escape mutants to emerge;
Elberse et al.[54] have made similar but distinct observations on
plasticity within the 6C capsular locus. Secondly, given that
surface proteins such as PspA and PspC are candidates for
inclusion in next-generation protein–based pneumococcal vac-
cines, the sequence variation seen in these proteins raises the
concern that the S. pneumoniae will respond to the introduction of
these vaccines with the same kind of rapid evolution seen after use
of polysaccharide vaccines. In other words, we may be facing an
example of Red Queen evolutionary dynamics,[55] where we may
need continual innovation in our vaccine repertoire to maintain
the same level of control of infection. It is also worrying to see the
emergence of antibiotic resistance in one of our 6C lineages.
This study confirms that genomic epidemiology surveys are no
longer the sole preserve of the large sequencing centres and suggest
that these techniques are poised to become cost-effective
replacements for existing S. pneumoniae typing methods such as
MLST, gene-specific PCR assays and PCR capsule typing. More
generally, high-throughput sequencing provides a new tool in our
armamentarium with the potential to keep pace with, or even
outrun, the evolution and spread of microbial pathogens as the
field developes further.
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